DataJoint, an advanced platform that blends computational databases with artificial intelligence, has raised $4.9 million in seed funding to improve data handling and speed up research in areas like neuroscience, cancer, and systems biology. The money came from several investors, including Nina Capital based in Barcelona, Inoca Capital Partners from Salt Lake City, and Capital Factory in Austin. Other investors who supported the round also joined, showing that DataJoint’s platform is gaining interest around the world. The company already works with clients and partners in many countries.

Health Technology Insights: Darcy Stowe Named CEO of Hearts for Hearing

This new funding will help DataJoint grow its business, improve its software-as-a-service platform, and increase its presence in the commercial life sciences and pharmaceutical industries in the U.S. and Europe. DataJoint’s platform combines various types of data and supports advanced AI and machine learning tools. It aims to solve common problems in research labs, such as disorganized data and challenges with reproducibility.

Health Technology Insights: Stratos Health and Superpower Team Up for Free Wellness Care

Recently, DataJoint was accepted into the ninth cohort of PharmStars, a top global accelerator for digital health innovations in the pharmaceutical industry. Being part of this program will allow DataJoint to work with pharmaceutical leaders and find new business opportunities through its innovative technology.

Dimitri Yatsenko, the company’s CTO, has a background in both technology and science. He started his career in Ukraine, then moved to the U.S. to study computer science. He has experience in databases for public safety, leading teams in medical imaging at GE Medical Systems, and working in neuroscience and AI startups. While pursuing a PhD at Baylor College of Medicine, he noticed gaps in how research data was managed and AI was developed. This led him to create DataJoint with a focus on strong engineering and scientific innovation.

DataJoint is being used by more than 100 labs, including well-known institutions like Johns Hopkins, UCSF, Harvard, and UCL. The platform automatically organizes and analyzes data, helping researchers deal with fragmented data and communication issues. As it grows in the pharmaceutical industry, DataJoint continues to support academic medical centers where its technology was first developed and tested. Jim Olson, CEO of DataJoint, said the funding will let the company reach more researchers and provide powerful AI-based data solutions to enhance life sciences research globally. Marta G. Zanchi, a founding partner at Nina Capital, praised the platform’s innovative features and its potential to impact scientific progress. She noted that DataJoint’s ability to simplify data workflows and improve reproducibility is essential for making scientific discoveries and healthcare innovations. She is excited to support the team as they scale their technology and change the way research is done worldwide.

Health Technology Insights: HPC and Kythera Labs Partner for Price Transparency Insights

To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com